Skip to content

Author

Hervé Tiriac

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Patient-Derived 3D Cell Models as New Approach Methodologies: Applications, Advances, and Challenges for Increased-Throughput Assays.

Patient-derived three-dimensional (3D) cell models are new approach methodologies (NAMs) that bridge the gap between traditional 2D cell cultures and in vivo models, making them attractive for increased-throughput screening (ITS) and secondary assays. In this review, we outline screening applications implementing patie...

Asimina S. Courelli, M. Macdonald, Hervé Tiriac · 0 citations
Sep 2026

Abstract B014: Leveraging dynamic epigenetic landscapes to decode tumor-associated macrophages in pancreatic ductal adenocarcinoma

Leveraging the MITF-dependent gene signature activated in macrophages, this work sought to address how MITF-associated enhancers are mechanistically influencing PDAC TAM functions as the tumor becomes more advanced and develops chemoresistance.

Debbie K. Ledezma, K. Gulay, Hervé Tiriac et al. · 0 citations
Sep 2026

Abstract A054: MICAL2 promotes oncogenic Kras -induced pancreatic cancer initiation by regulating RAC1-mediated acinar to ductal metaplasia

Pancreatic ductal adenocarcinoma (PDAC) is a deadly form of pancreatic cancer with the poorest 5-year survival rate among all solid cancers. Therefore, identifying effective therapeutic strategies is crucial for treating this disease. Using a genome-wide screening approach to find novel and targetable factors in huma...

Nirakar Rajbhandari, Deepa Sheik Pran Babu, E. Mose et al. · 0 citations
#protein folding Sep 2026

Abstract A065: Mutant GNAS drives cAMP/PDE/AMP–pAMPK signaling and therapeutic synergy with combined CDK4/6 and RAS inhibition in mucinous pancreatic neoplasia

Intraductal Papillary Mucinous Neoplasm (IPMN) are pre-malignant lesions of the pancreas with frequent co-mutations in KRAS and GNAS oncogenes. We recently reported pancreatic neoplasia from both primary and metastatic disease with KRAS/GNAS mutations are sensitive to single agent treatment with the FDA approved cell...

Deepa Sheik Pran Babu, Shira Yomtoubian, Ethan Tabibzadeh et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.